Rapid Therapeutic Science Laboratories, Inc.
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Rapid Therapeutic Science Laboratories, Inc. ("Rapid" or the "Company") on behalf of stockholders. A complaint has been filed by the United States Securities and Exchange Commission ("SEC") against Rapid. The complaint alleges that Rapid's Chief Executive Officer, Donal R. Schmidt, Jr. ("Schmidt"), drafted, disseminated, and/or filed press releases, investor communications, SEC filings, and website posts containing materially false and misleading claims intended to deceive Rapid’s investors regarding the Company’s business. The materially false and misleading information authored and/or approved by Schmidt included that: (1) Rapid had obtained an industrywide certification relating to manufacturing and product safety; (2) Rapid had secured major sales contracts; (3) Rapid had a laboratory that met international standards; (4) Rapid’s chief science officer was an engineer who held bachelor’s and doctoral degrees; (5) Rapid’s inhalers were safe and legal; and (6) Rapid’s stock listing application had been approved by Nasdaq.